www.fdanews.com/articles/198586-novavax-begins-south-african-efficacy-trial-for-covid-19-vaccine-hopeful
Novavax Begins South African Efficacy Trial for COVID-19 Vaccine Hopeful
August 18, 2020
Novavax announced that it has begun a phase 2b clinical trial of its COVID-19 vaccine candidate NVX-CoV2373 in South Africa.
The study will assess the efficacy of the Maryland-based biotech’s experimental vaccine in approximately 2,665 healthy patients, as well as its safety and immunogenicity in approximately 240 HIV-positive adults.
South Africa is experiencing a winter surge of COVID-19 disease, and the trial “has the potential to provide an early indication of efficacy, along with additional safety and immunogenicity data,” said Gregory Glenn, Novavax’s president of research and development.